We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

131 hedge funds and large institutions have $400M invested in Rigel Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more call options, than puts

Call options by funds: $916K | Put options by funds: $335K

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

10% more capital invested

Capital invested by funds: $365M → $400M (+$35M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.21% less ownership

Funds ownership: 9.52% → 9.31% (-0.21%)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

2% less funds holding

Funds holding: 133 → 131 (-2)

Holders
131
Holders Change
-2
Holders Change %
-1.5%
% of All Funds
2.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
39
Reduced
29
Closed
17
Calls
$916K
Puts
$335K
Net Calls
+$581K
Net Calls Change
-$267K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.66M
2
Two Sigma Investments
Two Sigma Investments
New York
+$2.11M
3
Marshall Wace
Marshall Wace
United Kingdom
+$1.85M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.48M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.43M

Top Sellers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
-$7.78M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.51M
3
Goldman Sachs
Goldman Sachs
New York
-$4.42M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$2.63M
5
Morgan Stanley
Morgan Stanley
New York
-$2.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$64.4M +$182K +7,972 +0.3%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$60.1M +$137K +6,004 +0.3%
BlackRock
3
BlackRock
New York
$36M +$672K +29,389 +2%
State Street
4
State Street
Massachusetts
$20.4M +$765K +33,467 +4%
Millennium Management
5
Millennium Management
New York
$18M +$250K +10,951 +2%
Vanguard Group
6
Vanguard Group
Pennsylvania
$16M +$3.66M +160,147 +35%
TA
7
Tamarack Advisers
California
$13.6M -$457K -20,000 -4%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$13.1M +$1.22M +53,321 +12%
O
9
OppenheimerFunds
New York
$12.8M – – –
RSCM
10
Rock Springs Capital Management
Maryland
$10.8M – – –
Citadel Advisors
11
Citadel Advisors
Florida
$10.5M -$6.51M -284,872 -41%
PAI
12
Palo Alto Investors
California
$10.2M – – –
NMC
13
NEA Management Company
Maryland
$8.34M – – –
CS
14
Candriam SCA
Luxembourg
$6.37M – – –
RPAM
15
Rhenman & Partners Asset Management
Sweden
$5.82M – – –
Goldman Sachs
16
Goldman Sachs
New York
$5.63M -$4.42M -193,412 -47%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$5.6M +$1.26M +54,991 +34%
Hudson Bay Capital Management
18
Hudson Bay Capital Management
Connecticut
$5.47M +$68.6K +3,000 +1%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$5.22M +$231K +10,124 +5%
Northern Trust
20
Northern Trust
Illinois
$5.16M -$6.04K -264 -0.1%
Deutsche Bank
21
Deutsche Bank
Germany
$5.03M +$910K +39,801 +25%
Morgan Stanley
22
Morgan Stanley
New York
$4.83M -$2.15M -94,163 -33%
Two Sigma Investments
23
Two Sigma Investments
New York
$4.29M +$2.11M +92,251 +124%
SCM
24
Sio Capital Management
New York
$4.14M -$1.31M -57,128 -26%
Macquarie Group
25
Macquarie Group
Australia
$4.11M – – –
1
2 3 4 5

RIGL Hedge Fund Activity: Q1 2019 in Review

131 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2019, worth a combined $400M — up 9.6% from $365M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RIGL and 16 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 39 added.

The largest buyer was Vanguard Group, adding an estimated $3.66M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $7.78M sold.

  • 131 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2019, down from 133 in Q4 2018.
  • Funds reported $400M of Rigel Pharmaceuticals stock for Q1 2019, up 9.6% quarter-over-quarter.
  • 16 funds opened new Rigel Pharmaceuticals positions in Q1 2019 and 17 closed out, a net change of -1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $3.66M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2019 was Sofinnova Investments, an estimated $7.78M sold.

Based on aggregated 13F filings for Q1 2019.